-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
Data -X- _ O
from -X- _ O
prospectively -X- _ O
planned -X- _ O
cohort -X- _ O
studies -X- _ O
on -X- _ O
risk -X- _ O
of -X- _ O
major -X- _ O
clinical -X- _ O
outcomes -X- _ O
and -X- _ O
prognostic -X- _ O
factors -X- _ O
for -X- _ O
patients -X- _ B-Patient
with -X- _ I-Patient
influenza -X- _ I-Patient
A -X- _ I-Patient
( -X- _ I-Patient
H1N1 -X- _ I-Patient
) -X- _ I-Patient
pdm09 -X- _ I-Patient
virus -X- _ I-Patient
are -X- _ O
limited. -X- _ O
In -X- _ O
2009 -X- _ O
, -X- _ O
in -X- _ O
order -X- _ O
to -X- _ O
assess -X- _ O
outcomes -X- _ O
and -X- _ O
evaluate -X- _ O
risk -X- _ O
factors -X- _ O
for -X- _ O
progression -X- _ O
of -X- _ O
illness -X- _ O
, -X- _ O
two -X- _ O
cohort -X- _ O
studies -X- _ O
were -X- _ O
initiated -X- _ O
: -X- _ O
FLU -X- _ O
002 -X- _ O
in -X- _ O
outpatients -X- _ O
and -X- _ O
FLU -X- _ O
003 -X- _ O
in -X- _ O
hospitalized -X- _ O
patients. -X- _ O
METHODS -X- _ O
AND -X- _ O
FINDINGS -X- _ O
: -X- _ O
Between -X- _ O
October -X- _ O
2009 -X- _ O
and -X- _ O
December -X- _ O
2012 -X- _ O
, -X- _ O
adults -X- _ B-Patient
with -X- _ I-Patient
influenza-like -X- _ I-Patient
illness -X- _ I-Patient
( -X- _ I-Patient
ILI -X- _ I-Patient
) -X- _ I-Patient
were -X- _ O
enrolled -X- _ O
; -X- _ O
outpatients -X- _ O
were -X- _ O
followed -X- _ O
for -X- _ O
14 -X- _ O
days -X- _ O
and -X- _ O
inpatients -X- _ O
for -X- _ O
60 -X- _ O
days. -X- _ O
Disease -X- _ O
progression -X- _ O
was -X- _ O
defined -X- _ O
as -X- _ O
hospitalization -X- _ O
and -X- _ O
/ -X- _ O
or -X- _ O
death -X- _ O
for -X- _ O
outpatients -X- _ O
, -X- _ O
and -X- _ O
hospitalization -X- _ O
for -X- _ O
> -X- _ O
28 -X- _ O
days -X- _ O
, -X- _ O
transfer -X- _ O
to -X- _ O
intensive -X- _ O
care -X- _ O
unit -X- _ O
( -X- _ O
ICU -X- _ O
) -X- _ O
if -X- _ O
enrolled -X- _ O
from -X- _ O
general -X- _ O
ward -X- _ O
, -X- _ O
and -X- _ O
/ -X- _ O
or -X- _ O
death -X- _ O
for -X- _ O
inpatients. -X- _ O
Infection -X- _ B-Outcome
was -X- _ I-Outcome
confirmed -X- _ I-Outcome
by -X- _ I-Outcome
RT-PCR. -X- _ I-Outcome
590 -X- _ I-Outcome
FLU -X- _ I-Outcome
002 -X- _ I-Outcome
and -X- _ I-Outcome
392 -X- _ I-Outcome
FLU -X- _ I-Outcome
003 -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
influenza -X- _ I-Outcome
A -X- _ I-Outcome
( -X- _ I-Outcome
H1N1 -X- _ I-Outcome
) -X- _ I-Outcome
pdm09 -X- _ I-Outcome
were -X- _ I-Outcome
enrolled -X- _ I-Outcome
from -X- _ I-Outcome
81 -X- _ I-Outcome
sites -X- _ I-Outcome
in -X- _ I-Outcome
17 -X- _ I-Outcome
countries -X- _ I-Outcome
at -X- _ I-Outcome
2 -X- _ I-Outcome
days -X- _ I-Outcome
( -X- _ I-Outcome
IQR -X- _ I-Outcome
1–3 -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
6 -X- _ I-Outcome
days -X- _ I-Outcome
( -X- _ I-Outcome
IQR -X- _ I-Outcome
4–10 -X- _ I-Outcome
) -X- _ I-Outcome
following -X- _ I-Outcome
ILI -X- _ I-Outcome
onset -X- _ I-Outcome
, -X- _ I-Outcome
respectively. -X- _ I-Outcome
Disease -X- _ I-Outcome
progression -X- _ I-Outcome
was -X- _ I-Outcome
experienced -X- _ I-Outcome
by -X- _ I-Outcome
29 -X- _ I-Outcome
( -X- _ I-Outcome
1 -X- _ I-Outcome
death -X- _ I-Outcome
) -X- _ I-Outcome
outpatients -X- _ I-Outcome
( -X- _ I-Outcome
5.1 -X- _ I-Outcome
% -X- _ I-Outcome
; -X- _ I-Outcome
95 -X- _ I-Outcome
% -X- _ I-Outcome
CI -X- _ I-Outcome
: -X- _ I-Outcome
3.4–7.2 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
80 -X- _ I-Outcome
inpatients -X- _ I-Outcome
[ -X- _ I-Outcome
death -X- _ I-Outcome
( -X- _ I-Outcome
32 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
hospitalization -X- _ I-Outcome
> -X- _ I-Outcome
28 -X- _ I-Outcome
days -X- _ I-Outcome
( -X- _ I-Outcome
43 -X- _ I-Outcome
) -X- _ I-Outcome
or -X- _ I-Outcome
ICU -X- _ I-Outcome
transfer -X- _ I-Outcome
( -X- _ I-Outcome
20 -X- _ I-Outcome
) -X- _ I-Outcome
] -X- _ I-Outcome
( -X- _ I-Outcome
21.6 -X- _ I-Outcome
% -X- _ I-Outcome
; -X- _ I-Outcome
95 -X- _ I-Outcome
% -X- _ I-Outcome
CI -X- _ I-Outcome
: -X- _ I-Outcome
17.5–26.2 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
Disease -X- _ I-Outcome
progression -X- _ I-Outcome
( -X- _ I-Outcome
death -X- _ I-Outcome
) -X- _ I-Outcome
for -X- _ I-Outcome
hospitalized -X- _ I-Outcome
patients -X- _ I-Outcome
was -X- _ I-Outcome
53.1 -X- _ I-Outcome
% -X- _ I-Outcome
( -X- _ I-Outcome
26.6 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
12.8 -X- _ I-Outcome
% -X- _ I-Outcome
( -X- _ I-Outcome
3.8 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
respectively -X- _ I-Outcome
, -X- _ I-Outcome
for -X- _ I-Outcome
those -X- _ I-Outcome
enrolled -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
ICU -X- _ I-Outcome
and -X- _ I-Outcome
general -X- _ I-Outcome
ward. -X- _ I-Outcome
In -X- _ I-Outcome
pooled -X- _ I-Outcome
analyses -X- _ I-Outcome
for -X- _ I-Outcome
both -X- _ I-Outcome
studies -X- _ I-Outcome
, -X- _ I-Outcome
predictors -X- _ I-Outcome
of -X- _ I-Outcome
disease -X- _ I-Outcome
progression -X- _ I-Outcome
were -X- _ I-Outcome
age -X- _ I-Outcome
, -X- _ I-Outcome
longer -X- _ I-Outcome
duration -X- _ I-Outcome
of -X- _ I-Outcome
symptoms -X- _ I-Outcome
at -X- _ I-Outcome
enrollment -X- _ I-Outcome
and -X- _ I-Outcome
immunosuppression. -X- _ I-Outcome
Patients -X- _ I-Outcome
hospitalized -X- _ I-Outcome
during -X- _ I-Outcome
the -X- _ I-Outcome
pandemic -X- _ I-Outcome
period -X- _ I-Outcome
had -X- _ I-Outcome
a -X- _ I-Outcome
poorer -X- _ I-Outcome
prognosis -X- _ I-Outcome
than -X- _ I-Outcome
in -X- _ I-Outcome
subsequent -X- _ I-Outcome
seasons. -X- _ I-Outcome
CONCLUSIONS -X- _ O
: -X- _ O
Patients -X- _ O
with -X- _ O
influenza -X- _ O
A -X- _ O
( -X- _ O
H1N1 -X- _ O
) -X- _ O
pdm09 -X- _ O
, -X- _ O
particularly -X- _ O
when -X- _ O
requiring -X- _ O
hospital -X- _ O
admission -X- _ O
, -X- _ O
are -X- _ O
at -X- _ O
high -X- _ O
risk -X- _ O
for -X- _ O
disease -X- _ O
progression -X- _ O
, -X- _ O
especially -X- _ O
if -X- _ O
they -X- _ O
are -X- _ O
older -X- _ O
, -X- _ O
immunodeficient -X- _ O
, -X- _ O
or -X- _ O
admitted -X- _ O
late -X- _ O
in -X- _ O
infection. -X- _ O
These -X- _ O
data -X- _ O
reinforce -X- _ O
the -X- _ O
need -X- _ O
for -X- _ O
international -X- _ O
trials -X- _ O
of -X- _ O
novel -X- _ O
treatment -X- _ O
strategies -X- _ O
for -X- _ O
influenza -X- _ O
infection -X- _ O
and -X- _ O
serve -X- _ O
as -X- _ O
a -X- _ O
reminder -X- _ O
of -X- _ O
the -X- _ O
need -X- _ O
to -X- _ O
monitor -X- _ O
the -X- _ O
severity -X- _ O
of -X- _ O
seasonal -X- _ O
and -X- _ O
pandemic -X- _ O
influenza -X- _ O
epidemics -X- _ O
globally. -X- _ O
TRIAL -X- _ O
REGISTRATION -X- _ O
: -X- _ O
ClinicalTrials.gov -X- _ O
Identifiers -X- _ O
: -X- _ O
FLU -X- _ O
002- -X- _ O
NCT01056354 -X- _ O
, -X- _ O
FLU -X- _ O
003- -X- _ O
NCT01056185 -X- _ O
. -X- _ O

